MY ACCOUNT | NEWSLETTER |

AKC Canine Health Foundation marks pet cancer awareness month with new research grants


The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, marks Pet Cancer Awareness Month each May to highlight the impact of its funded canine cancer research. Already in 2023, CHF has awarded three new grants to study canine lymphoma, anal sac carcinoma, and bone cancer, according to a May 1 news release.

Cancer remains a major concern for dog owners and veterinary professionals. Approximately one quarter of CHF's active research portfolio is usually dedicated to studies exploring more accurate diagnostic tests and new treatments for canine cancer. Since 1995, CHF and its donors have invested more than $17.7 million to study cancer at the molecular level, conduct clinical trials for new treatments, and understand how the immune system interacts with cancer cells.

The newly awarded research grants are:

  • Grant 03144: Lomustine, Asparaginase, Procarbazine and Prednisone (LAPP) for Canine Multicentric Lymphoma: A Practical Multiagent Chemotherapy Protocol that Avoids Injectable Cytotoxics, Principal Investigator Dr. Douglas Thamm, VMD, Colorado State University. A clinical trial of a new chemotherapy protocol using drugs that do not require special handling and therefore may be more widely available than currently used chemotherapy protocols.
  • Grant 03103: Identification of Genetic Mutations in Anal Sac Carcinoma Development in English Cocker Spaniels, Part II – Validation, Principal Investigator Shaying Zhao, University of Georgia. Investigators will explore the genetic mutations that predispose English Cocker Spaniels to this cancer of the anal sacs.
  • Grant 03095-A: Cell-Specific Expression of MicroRNAs in Primary and Metastatic Canine Osteosarcoma, Principal Investigator Dr. Geoffrey Wood, DVM, University of Guelph. Investigators will determine which cells produce a promising canine bone cancer biomarker that could help predict tumor behavior and dog survival time.

"CHF invests heavily in research to better understand canine cancer, which is so often a devastating and heartbreaking disease," said Dr. J. Charles Garvin, Chairman of the CHF Board of Directors. "In addition to helping our dogs live longer, healthier lives, this research often provides insight into similar human cancers. We know that both ends of the leash benefit when we work together to fight cancer, giving us more time with our beloved dogs."

These studies are part of CHF's $4.8 million research portfolio of active canine cancer grants. To learn more about the Foundation's commitment to canine cancer research, including educational resources and ways to participate in canine cancer research, visit akcchf.org/caninecancer.

About CHF

Since 1995, the AKC Canine Health Foundation has leveraged the power of science to address the health needs of all dogs. With more than $67.5 million in funding to date, the Foundation provides grants for the highest quality canine health research and shares information on the discoveries that help prevent, treat and cure canine diseases. The Foundation meets and exceeds industry standards for fiscal responsibility, as demonstrated by their highest four-star Charity Navigator rating and Candid Platinum Seal of Transparency. Learn more at www.akcchf.org.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

New grad programs advance educational landscape at UF

Like0
Dislike0

Neogen Announces First-Quarter Earnings Release Date

Like0
Dislike0

Surgical interventions and outcome in a population of feline trauma patients

Like0
Dislike0

Applications of Evidence-Based Medicine: Cranial Cruciate Ligament Injury Repair in the Dog

Like0
Dislike0

Use of Antibiotics and Antimicrobial Resistance in Veterinary Medicine as Exemplified by the Swine Pathogen Streptococcus suis

Like1
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top